Bristol-Myers Squibb
BMY
$65.47
+0.24%
Bristol-Myers Squibb Co. is a global biopharmaceutical company that discovers, develops, and markets innovative medicines for serious diseases, primarily in oncology, immunology, and cardiovascular care. As a leader in immuno-oncology, with blockbuster drugs like Opdivo and Eliquis, the company holds a strong competitive position in the industry, though it faces patent expirations on key legacy products. The current investor narrative centers on the company's successful pivot to newer growth brands, as evidenced by a 12% jump in sales from its growth portfolio in Q1 2026, which drove a strong earnings beat and a surge in the stock price. Additionally, the recent FDA approval of a rival's surgical robot and competitive threats in psoriasis highlight the ongoing challenges and opportunities in the dynamic pharmaceutical landscape.…
BMY
Bristol-Myers Squibb
$65.47
Related headlines
BMY 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bristol-Myers Squibb's 12-month outlook, with a consensus price target around $64.91 and implied upside of -0.8% versus the current price.
Average Target
$64.91
0 analysts
Implied Upside
-0.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $80
Analyst target range
The stock is covered by 24 analysts, with a consensus recommendation of 'Buy' (mean rating 2.5). The average target price is $63.96, which is 2.1% below the current price of $65.31, implying a slight downside. The target range is wide, from $40.00 to $75.00, reflecting high uncertainty about the company's future, particularly regarding pipeline execution and competitive pressures. The low target suggests concerns about patent expirations and market share losses, while the high target likely assumes successful launches of new drugs and margin expansion. Recent ratings actions have been mostly neutral or positive, with no major downgrades, indicating a stable but cautious sentiment among analysts.
BMY Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +50.8% and a 6-month change of +18.6%. Currently trading at $65.31, it sits at 99.5% of its 52-week range (low: $42.52, high: $65.66), indicating the stock is near its highs, reflecting robust momentum and investor optimism. This positioning near the top of the range suggests the market is rewarding the company's recent execution, but also raises the risk of overextension in the short term.
Beta
0.23
0.23x market volatility
Max Drawdown
-13.4%
Largest decline past year
52-Week Range
$43-$68
Price range past year
Annual Return
+48.0%
Cumulative gain past year
| Period | BMY Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | +1.7% |
| 3m | +15.0% | +4.7% |
| 6m | +13.6% | +10.4% |
| 1y | +48.0% | +21.9% |
| ytd | +22.5% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BMY Fundamental Analysis
Revenue growth is modest but steady, with Q1 2026 revenue of $11.49 billion, up 2.6% year-over-year, and a slight sequential increase from Q4 2025's $12.50 billion. The company's growth portfolio, including Breyanzi ($411M), Camzyos ($314M), and Reblozyl ($555M), is driving the narrative, while legacy drugs like Revlimid ($349M) are declining as expected. This mixed trend suggests the company is successfully transitioning, but overall growth remains subdued, which is typical for a large-cap pharma facing patent cliffs.
Quarterly Revenue
$11.5B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
70.2%
Latest Quarter
Free Cash Flow
$11.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BMY Overvalued?
Given the company's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 15.6x, while the forward PE is 10.1x, indicating the market expects significant earnings growth, likely driven by cost savings and new product uptake. The gap between trailing and forward PE suggests a positive growth outlook, with the forward multiple implying a 35% discount to trailing, which is attractive if the company can deliver on its pipeline and margin expansion plans.
PE
15.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.7x
Enterprise Value Multiple